Dermapharm Holding SECHIX:DMPD 80 EV-to-EBITDA is 9.17 as of Jul. 11, 2026, which is 8% below its 10-year median of 9.92. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €39.87. The stock has 10 warning signs investors should review. Among 739 Drug Manufacturers companies, Dermapharm Holding SE ranks better than 67.25% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Dermapharm Holding SE's enterprise value is €3,089 Mil.
Dermapharm Holding SE's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €337 Mil. Therefore, Dermapharm Holding SE's EV-to-EBITDA for today is 9.17.
The historical rank and industry rank for Dermapharm Holding SE's EV-to-EBITDA or its related term are showing as below:
CHIX:DMPd'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.97 Med: 9.92 Max: 21.78
Current: 9.17
During the past 13 years, the highest EV-to-EBITDA of Dermapharm Holding SE was 21.78. The lowest was 4.97. And the median was 9.92.
CHIX:DMPd's EV-to-EBITDA is ranked better than 67.25% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.94
vs CHIX:DMPd: 9.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Dermapharm Holding SE (CHIX:DMPd) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dermapharm Holding SE's PE Ratio (TTM) for today is calculated as:
Dermapharm Holding SE's share price for today is €46.175.
Dermapharm Holding SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.680.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Dermapharm Holding SE EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Dermapharm Holding SE's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DMPD vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's EV-to-EBITDA falls into.
Dermapharm Holding SE's current Enterprise Value is €3,089 Mil.
Dermapharm Holding SE's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €337 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermapharm Holding SE (CHIX:DMPD) has a EV-to-EBITDA of 9.17 as of Jul. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dermapharm Holding SE. This is near median its historical median of 9.92. Over the past decade, Dermapharm Holding SE's EV-to-EBITDA has ranged from 4.97 to 21.78. According to the industry distribution chart, Dermapharm Holding SE ranks #242 out of 739 companies in the Drug Manufacturers industry, placing it in the top 32.7%.
Is Dermapharm Holding SE's EV-to-EBITDA too high?
Dermapharm Holding SE's current EV-to-EBITDA of 9.17 is near median its 10-year median of 9.92. Over the past 10 years, this metric has ranged from a low of 4.97 to a high of 21.78. The Drug Manufacturers industry median EV-to-EBITDA is 12.94. Dermapharm Holding SE's value of 9.17 is 29.1% below this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #242 out of 739 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #242 out of 739 companies for EV-to-EBITDA. This puts Dermapharm Holding SE in the upper half of its industry. The industry median EV-to-EBITDA is 12.94. Dermapharm Holding SE's value of 9.17 is 29.1% below this benchmark. Historically, Dermapharm Holding SE's own EV-to-EBITDA has ranged from 4.97 to 21.78 over the past decade. While the company's 10-year median is 9.92 vs. the industry median of 12.94, Dermapharm Holding SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.94, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current EV-to-EBITDA of 9.17 is 29.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dermapharm Holding SE. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current EV-to-EBITDA is 9.17, which is near median its own 10-year median of 9.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current EV-to-EBITDA of 9.17. The stock's GF Value™ is €39.87, compared to a current price of €46.18 — trading 15.8% above its estimated fair value. The current EV-to-EBITDA is 9.17, which is near median its 10-year median of 9.92 and 29.1% below the Drug Manufacturers industry median of 12.94. Dermapharm Holding SE's overall GF Score™ is 80/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current EV-to-EBITDA is 9.17 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.18 is trading 15.8% above its estimated GF Value™ of €39.87.
Key valuation signals for CHIX:DMPD:
EV-to-EBITDA: 9.17 (near median its 10-year median of 9.92)
GF Value™: €39.87 vs. price of €46.18 (15.8% above fair value)
Industry Position: 29.1% below the Drug Manufacturers median (#242 of 739)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
